282.80
前日終値:
$288.29
開ける:
$276.35
24時間の取引高:
1.39M
Relative Volume:
2.58
時価総額:
$19.84B
収益:
$1.98B
当期純損益:
$420.90M
株価収益率:
48.42
EPS:
5.84
ネットキャッシュフロー:
$218.20M
1週間 パフォーマンス:
+0.80%
1か月 パフォーマンス:
+2.43%
6か月 パフォーマンス:
+52.21%
1年 パフォーマンス:
+46.92%
Insulet Corporation Stock (PODD) Company Profile
PODD を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
PODD
Insulet Corporation
|
282.80 | 19.84B | 1.98B | 420.90M | 218.20M | 5.84 |
![]()
ABT
Abbott Laboratories
|
134.92 | 234.01B | 41.95B | 13.40B | 6.49B | 7.65 |
![]()
BSX
Boston Scientific Corp
|
104.49 | 154.20B | 16.75B | 1.85B | 2.37B | 1.25 |
![]()
SYK
Stryker Corp
|
382.78 | 146.06B | 22.60B | 2.99B | 3.49B | 7.76 |
![]()
MDT
Medtronic Plc
|
89.94 | 115.42B | 33.20B | 4.26B | 5.47B | 3.29 |
![]()
EW
Edwards Lifesciences Corp
|
73.30 | 43.23B | 5.72B | 4.17B | 490.10M | 6.97 |
Insulet Corporation Stock (PODD) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-11-06 | 開始されました | Bernstein | Outperform |
2024-05-30 | 開始されました | Redburn Atlantic | Buy |
2024-05-07 | アップグレード | Wolfe Research | Peer Perform → Outperform |
2023-12-21 | アップグレード | Robert W. Baird | Neutral → Outperform |
2023-12-04 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2023-10-02 | アップグレード | Jefferies | Hold → Buy |
2023-08-21 | アップグレード | Citigroup | Neutral → Buy |
2023-08-21 | ダウングレード | Robert W. Baird | Outperform → Neutral |
2023-05-30 | 再開されました | Morgan Stanley | Equal-Weight |
2023-01-26 | 開始されました | Wolfe Research | Peer Perform |
2022-11-04 | アップグレード | Piper Sandler | Neutral → Overweight |
2022-10-18 | 開始されました | Barclays | Equal Weight |
2022-10-12 | 開始されました | Jefferies | Hold |
2022-07-11 | ダウングレード | Citigroup | Buy → Neutral |
2022-03-02 | 再開されました | BofA Securities | Buy |
2022-02-03 | アップグレード | BTIG Research | Neutral → Buy |
2022-02-02 | アップグレード | UBS | Neutral → Buy |
2022-01-31 | アップグレード | Oppenheimer | Perform → Outperform |
2021-07-21 | 再開されました | Cowen | Outperform |
2021-05-25 | 開始されました | Barclays | Overweight |
2021-04-01 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
2021-03-19 | アップグレード | Canaccord Genuity | Hold → Buy |
2021-01-29 | ダウングレード | Piper Sandler | Overweight → Neutral |
2020-12-16 | ダウングレード | Citigroup | Buy → Neutral |
2020-07-28 | 開始されました | Wells Fargo | Overweight |
2020-04-24 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
2020-04-03 | 開始されました | BofA/Merrill | Neutral |
2020-03-31 | ダウングレード | Berenberg | Buy → Hold |
2020-03-05 | 開始されました | Citigroup | Buy |
2019-12-10 | 開始されました | CFRA | Sell |
2019-10-23 | 開始されました | Stifel | Hold |
2019-10-18 | ダウングレード | Canaccord Genuity | Buy → Hold |
2019-10-14 | ダウングレード | BTIG Research | Buy → Neutral |
2019-10-04 | ダウングレード | UBS | Buy → Neutral |
2019-10-03 | ダウングレード | Guggenheim | Buy → Neutral |
2019-08-06 | アップグレード | JP Morgan | Neutral → Overweight |
2019-06-10 | ダウングレード | Northland Capital | Outperform → Market Perform |
2019-05-06 | アップグレード | BTIG Research | Neutral → Buy |
2018-04-20 | 開始されました | Berenberg | Buy |
2018-02-22 | 繰り返されました | Barclays | Overweight |
2018-01-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
2017-11-03 | アップグレード | Canaccord Genuity | Hold → Buy |
2017-09-15 | 開始されました | Barclays | Overweight |
すべてを表示
Insulet Corporation (PODD) 最新ニュース
Insulet Q4 2024 revenue up 17.2% to USD 597.5M - Medical Buyer
Insulet Stock: Aiding Patients And Investors (NASDAQ:PODD) - Seeking Alpha
Insulet’s Earnings Highlight Omnipod Success Amid Challenges - TipRanks
Insulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst - Benzinga
Insulet stock price target raised to $293 by Stifel - Investing.com Canada
Stifel Nicolaus Adjusts Insulet Price Target to $293 From $245 -February 21, 2025 at 09:21 am EST - Marketscreener.com
Leerink Partners Adjusts Insulet Price Target to $314 From $278 -February 21, 2025 at 09:19 am EST - Marketscreener.com
Assessing Insulet: Insights From 6 Financial Analysts - Benzinga
PODD Stock Falls Despite Q4 Earnings and Revenue Beat, Margins Rise - Yahoo Finance
Insulet Corporation (NASDAQ:PODD) Q4 2024 Earnings Call Transcript - Insider Monkey
Insulet stock target raised to $324 by Canaccord Genuity - Investing.com South Africa
Insulet Corporation (PODD) PT Raised to $293 at Stifel - StreetInsider.com
Insulet stock price target raised to $310 by BTIG - Investing.com South Africa
Insulet Corporation (PODD) PT Raised to $324 at Canaccord Genuity - StreetInsider.com
Insulet Updates Equity Agreements for Fiscal 2025 - TipRanks
INSULET CORP SEC 10-K Report - TradingView
Insulet Corporation (PODD) PT Raised to $310 at BTIG - StreetInsider.com
Blue Owl Capital, Insulet, Unity Software - TradingView
Insulet Corp (PODD) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Expansion Amidst Challenges - GuruFocus.com
Insulet’s Revenue Surpasses $2 Billion with Strong Growth - TipRanks
Insulet Corp (PODD) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Expansion ... - Yahoo Finance
Insulet Reports Full Year 2024 Revenue Increase of 22% and Fourth Quarter 2024 Revenue Increase of 17% Year-Over-Year - BioSpace
Insulet: Q4 Earnings Snapshot - Thehour.com
Earnings call transcript: Insulet beats Q4 2024 forecasts, stock dips By Investing.com - Investing.com Canada
Insulet earnings beat by $0.12, revenue topped estimates - Investing.com
Insulet Corp (PODD) Q4 Earnings: EPS of $1.39 Beats Estimate, Revenue Surpasses Expectations at $597.5 Million - GuruFocus.com
Compared to Estimates, Insulet (PODD) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
Insulet (PODD) Q4 Earnings and Revenues Top Estimates - Yahoo Finance
Insulet Corporation (NASDAQ:PODD) Reports Strong Q4 2024 PerformanceNews and Statistics - IndexBox, Inc.
Insulet beats quarterly profit estimates on insulin pump demand - Reuters
Insulet’s (NASDAQ:PODD) Q4: Beats On Revenue, Quarterly Revenue Guidance Slightly Exceeds Expectations - Yahoo Finance
Insulet: Q4 Earnings Snapshot -February 20, 2025 at 04:34 pm EST - Marketscreener.com
Insulet beats Q4 estimates, sees strong 2025 growth By Investing.com - Investing.com Australia
Insulet beats Q4 estimates, sees strong 2025 growth - Investing.com
Insulet Q4 Adjusted EPS Decreases, Revenue Rises -February 20, 2025 at 04:11 pm EST - Marketscreener.com
Agree To Purchase Insulet Corp At $200, Earn 36.5% Annualized Using Options - Nasdaq
Insulet Earnings: What To Look For From PODD - The Globe and Mail
Insulet Earnings: What To Look For From PODD By Stock Story - Investing.com Canada
(PODD) Trading Report - Stock Traders Daily
Insulet (NASDAQ:PODD) Is Experiencing Growth In Returns On Capital - Simply Wall St
Certuity LLC Invests $245,000 in Insulet Co. (NASDAQ:PODD) - MarketBeat
Summit Trail Advisors LLC Acquires Shares of 1,882 Insulet Co. (NASDAQ:PODD) - MarketBeat
Sumitomo Mitsui DS Asset Management Company Ltd Grows Position in Insulet Co. (NASDAQ:PODD) - MarketBeat
PODDInsulet to Assume Distribution and Commercial Support for Its Omnipod® System in Europe - br.ADVFN.com
Choreo LLC Decreases Stock Position in Insulet Co. (NASDAQ:PODD) - MarketBeat
Stay Ahead of the Game With Insulet (PODD) Q4 Earnings: Wall Street's Insights on Key Metrics - Yahoo Finance
Insulet Co. (NASDAQ:PODD) Stake Boosted by Sumitomo Mitsui Trust Group Inc. - MarketBeat
Insulet Co. (NASDAQ:PODD) Shares Sold by Stephens Investment Management Group LLC - MarketBeat
Insulet Corporation vs Menarini Diagnostics and EOFlow - Solicitors Journal
Tubeless Insulin Pumps Market to Grow with Leading Key Players - openPR
Insulet Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Insulet Corporation (PODD) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):